Oncolytics Biotech Inc. ONCY
Set alert
0.42 USD -0.01 -1.46%
As of Nov 2, 10:06 AM ET
0.4152 Day range 0.4255
0.41 52-week range 1.30
- YTD
- -51.82%
- 1 year
- -64.77%
- Open
- 0.4255
- Prev close
- 0.4254
- Mkt cap
- 54.95M
- Vol
- 88.45K
- Avg vol
- 1.04M
- EPS
- -0.35
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.4152
- High
- 0.4255
- Forward P/E
- -3.02
- Beta
- 1.51
- Short ratio
- 3.51
- Inst. own
- 1.76%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.04
- 200-d avg
- 1.04
- 1y target
- 4.85
3M chart
Signals (17)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 29, 2026 | 4 days ago |
| RSI: Oversold | Oct 26, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 22, 2026 | 1 week ago |
| RSI: Oversold | Oct 1, 2026 | 1 month ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 8, 2026 | 1 month ago |
| SMA: Bearish | Sep 4, 2026 | 1 month ago |
| SMA: Bullish | Sep 2, 2026 | 2 months ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| SMA: Bullish | Aug 28, 2026 | 2 months ago |
| SMA: Bearish | Aug 27, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bullish | Aug 21, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bullish | Aug 18, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
Key statistics
- Market cap
- 69.81M
- Enterprise value
- 55.56M
- Trailing P/E
- 0.00
- Forward P/E
- -3.02
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.45
- EPS (TTM)
- -0.25
- Beta
- 1.51
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -15.77M
- Total cash
- 24.85M
- Total debt
- 1.12M
- Return on equity
- -138.22%
- Shares outstanding
- 77.07M
- Short % of float
- 3.89%
- 50-day average
- 1.04
- 200-day average
- 1.04
Analyst view
Consensus: none
Price target (mean) 4.85
Ratings (0m) 8 8 buy · 0 hold · 0 sell
- Strong buy5
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.1345.
Financials — quick view
ONCY Revenue — quarterly 0
ONCY Net income — quarterly -9.44M
ONCY EPS — quarterly -0.08
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.08 | -0.09 | -0.01 | -12.50% |
| Aug 1, 2024 | Jun 1, 2024 | -0.08 | -0.07 | +0.01 | +12.50% |
| May 9, 2024 | Mar 1, 2024 | -0.09 | -0.07 | +0.02 | +22.22% |
| Mar 7, 2024 | Dec 1, 2023 | -0.11 | -0.04 | +0.07 | +63.64% |
| Nov 3, 2023 | Sep 1, 2023 | -0.07 | -0.10 | -0.03 | -42.86% |
| Aug 14, 2023 | Jun 1, 2023 | -0.09 | -0.09 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 21, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 4, 2024 | Raymond James | init | — | Outperform |
| Mar 8, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About Oncolytics Biotech Inc.
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- oncolyticsbiotech.com
News
- Oncolytics Biotech Announces Its Group 4 Of Phase 1/2 GOBLET Trial Of Pelareorep In Combination With Atezolizumab Failed to Reach Median Overall Survival
- Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers
- Oncolytics Biotech To Present Trail-In-Progress Abstract, E-Poster For Its REO 033 Trial At European Society For Medical Oncology
- Oncolytics Biotech Anticipates Reporting Final Results From Group 4 Of Its GOBLET Phase 1/2 Trial In Q4 For Pelareorep With Atezolizumab To Treat Squamous Cell Anal Carcinoma; To Receive Payment Under Grant From Pancreatic Cancer Action Network This Quarter
- Oncolytics Biotech Expands Pelareorep Patent Protection Strategy Through 2044
- Oncolytics Biotech Publishes Data On Pelareorep Immunotherapy In Proceedings Of The National Academy Of Sciences
- Oncolytics Biotech's All Planned Facilities For Part A Of REO 033 Trial Activated, Multiple Participants Admitted
- Oncolytics Biotech Announces Pelareorep Lowered Tumor Growth Compared To Control During Initial Treatment Period
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- HC Wainwright & Co. Maintains Buy on Oncolytics Biotech, Lowers Price Target to $5
Your note
Sign in to keep a note on ONCY — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| International Assets Investment Management, LLC | 0.26% | 198,400 | 179.71K | Jun 29, 2024 |
| Seeds Investor LLC | 0.25% | 189,941 | 172.05K | Sep 29, 2024 |
| Goldman Sachs Group Inc | 0.11% | 84,998 | 76.99K | Sep 29, 2024 |
| Royal Bank of Canada | 0.10% | 74,546 | 67.52K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.10% | 79,249 | 71.78K | Sep 29, 2024 |
| Commonwealth Equity Services, LLC | 0.08% | 61,114 | 55.36K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.05% | 41,942 | 37.99K | Oct 30, 2024 |